Potential Kodak deal paused until insider trading 'allegations are cleared'

The SEC is now in the early stages of a probe, according to The Wall Street Journal, which cited anonymous sources.

A government agency said a potential deal to have Eastman Kodak help make generic drugs is being paused until allegations of insider trading at the once mighty photography company are cleared.

Recent allegations of wrongdoing raise serious concerns, said the U.S. International Development Finance Corporation in a tweet late Friday. We will not proceed any further unless these allegations are cleared.

The International Development Finance Corporation did not respond for a request for comment Saturday.

Kodak, which is based in Rochester, New York, declined to comment.

Last month, the International Development Finance Corporation signed a letter of intent to potentially give Kodak a $765 million loan to help pay for factory changes needed to make pharmaceutical ingredients in short supply in the US.

News of the potential deal sent the company's stock price surging.

But last week, Democratic Senator Elizabeth Warren asked the Securities and Exchange Commission to investigate whether insider trading laws had been broken, citing unusual trading activity before the deal was announced.

The SEC is now in the early stages of a probe, according to The Wall Street Journal, which cited anonymous sources. The SEC has declined to comment on the report.

On Friday, Kodak announced it was conducting an internal review related to the loan deal.

The loan, which hasn't been finalised, was expected to be used to expand plants in Rochester and St. Paul, Minnesota.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel